Concepedia

Konstantin Penkov

KP

18

Publications

3.8K

Citations

16

H-Index

2018

Active since

Affiliations

Pfizer (United States)(Current)

The University of Texas MD Anderson Cancer Center

Pfizer (Italy)

Institut Gustave Roussy

Dana-Farber Cancer Institute

Konstantin Penkov is an author at Pfizer (United States) specializing in medicine, oncology, and cancer therapeutics.

Top concepts

Publications per year

2018–2024

18

Publications

18

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen et al. · New England Journal of Medicine · 2019 · 2.5K citations · Full text

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Robert J. Motzer, Paul B. Robbins, Thomas Powles et al. · Nature Medicine · 2020 · 503 citations · Full text

, , +8

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Fiona Blackhall, Kevin Jao, Laurent Greillier et al. · Journal of Thoracic Oncology · 2021 · 239 citations · Full text

Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

Toni K. Choueiri, Laurence Albigès, John B.A.G. Haanen et al. · Journal of Clinical Oncology · 2019 · 99 citations

, , +25

Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study

Lauren A. Byers, Dmitry Bentsion, Steven Gans et al. · Clinical Cancer Research · 2021 · 72 citations · Full text

Rows per page

1–5 of 18